Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 8/20 | 0.33 |
| ▸ | CNR2 | P34972 | 7/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18411002 | 0.98 | CNR1 (0.32) | CNR1CNR2GPR84TLR8 | |
| SCHEMBL18950499 | 0.94 | GPR84 (0.31) | CNR1CNR2GPR84 | |
| SCHEMBL19573801 | 0.87 | CNR1 (0.38) | CNR1CNR2 | |
| SCHEMBL21718623 | 0.82 | CNR2 (0.33) | CNR1CNR2 | |
| SCHEMBL25913941 | 0.82 | KCNH2 (0.30) | — | |
| SCHEMBL21719828 | 0.81 | — | — | |
| SCHEMBL21719659 | 0.81 | XDH (0.30) | — | |
| SCHEMBL21719672 | 0.81 | MEN1 (0.31) | — | |
| SCHEMBL18874801 | 0.81 | LMNA (0.33) | CNR1CNR2TLR8 | |
| SCHEMBL21719673 | 0.81 | GGPS1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180050052-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-02-22 | — | — | US | disclosed |
| US-9725448-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170066764-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180050052-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | CNR1 498/4885CNR2 1647/4885GPR84 1235/4885 |
| US-20170066764-A1 | NEPRILYSIN INHIBITORS | MME, REN, EDNRB | CNR1 679/4885CNR2 1498/4885GPR84 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.